17-Phenyl-18,19,20-trinor-cis-4,5-didehydro-PGF.sub.1.beta. compounds
AssigneeThe Upjohn Company
InventorBarney J. Magerlein
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe Upjohn Company
InventorBarney J. Magerlein
Estimating the term…
The disclosure includes novel compounds which differ from the known prostaglandins PGF.sub.2.alpha., PGF.sub.2.beta., PGE.sub.2, PGA.sub.2, and PGB.sub.2 in that the carbon-carbon double bond in the carboxyl-terminated chain of the novel compounds is in the 4,5-position rather than in the 5,6-position, and in that there is a phenyl or substituted phenyl group in the other chain of the novel compounds. These novel compounds are useful for a variety of pharmacological purposes, including abortion, labor induction, and reduction of gastric secretion.
An optically active compound of the formula:
Dependencies are inferred from the claim text.
Drawings are temporarily unavailable. Open the PDF at USPTO
From the US filing history. Foreign family members aren’t listed.
No references of this kind are recorded.
Condensed with a ring other than six-membered: not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
Compounds containing a five-membered ring having two side-chains in ortho position to
Oxygen atoms: only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
Ortho- or peri-condensed with carbocyclic rings or ring systems: condensed with rings other than six-membered or with ring systems containing such…
Term ended 27 Dec 1994 (estimated)
USPTO file history isn’t available for this patent, so only indexed dates are shown.
The present invention relates to prostaglandin analogs for which the essential material constituting a disclosure therefor is incorporated by reference here from U.S. Pat. No. 4,032,561, issued June 28, 1977.